TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal.

[1]  H. Weiner,et al.  Improved relapse recovery in paediatric compared to adult multiple sclerosis. , 2020, Brain : a journal of neurology.

[2]  G. Cutter,et al.  Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing , 2019, Neurology.

[3]  L. Krupp,et al.  A Review of Available Treatments, Clinical Evidence, and Guidelines for Diagnosis and Treatment of Pediatric Multiple Sclerosis in the United States , 2019, Journal of child neurology.

[4]  D. Oleske,et al.  Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature , 2019, Journal of child neurology.

[5]  M. Sormani,et al.  Clinical trials of disease-modifying agents in pediatric MS , 2019, Neurology.

[6]  D. Arnold,et al.  Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis , 2018, The New England journal of medicine.

[7]  Ian T. Rossman,et al.  Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis , 2017, Neurotherapeutics.

[8]  J. Dalén,et al.  New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal , 2017, Multiple sclerosis.

[9]  R. Alroughani,et al.  The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. , 2017, Pediatric neurology.

[10]  L. Chibnik,et al.  Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis , 2017, Neurology.

[11]  A. Ghezzi,et al.  Pediatric multiple sclerosis , 2016, Neurology.

[12]  T. Chitnis,et al.  Use of Disease-Modifying Therapies in Pediatric MS , 2016, Current Treatment Options in Neurology.

[13]  M. Filippi,et al.  Natalizumab in the pediatric MS population: results of the Italian registry , 2015, BMC Neurology.

[14]  P. Huppke,et al.  Extensive acute axonal damage in pediatric multiple sclerosis lesions , 2015, Annals of neurology.

[15]  Alan J. Thompson,et al.  Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity , 2014, Neurology.

[16]  B. Healy,et al.  Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. , 2014, Multiple sclerosis and related disorders.

[17]  L. Kappos,et al.  Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  A. Ghezzi,et al.  International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions , 2013, Multiple sclerosis.

[19]  D. Prayer,et al.  Natalizumab therapy for highly active pediatric multiple sclerosis. , 2013, JAMA neurology.

[20]  M. Filippi,et al.  Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases , 2013, Multiple sclerosis.

[21]  J. De Pedro-Cuesta,et al.  Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese Data , 2012, Neuroepidemiology.

[22]  A. Ghezzi,et al.  Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.

[23]  M. Ramanathan,et al.  Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. , 2011, Archives of neurology.

[24]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[25]  M. Filippi,et al.  Safety and efficacy of natalizumab in children with multiple sclerosis , 2010, Neurology.

[26]  B. Weinstock-Guttman,et al.  Natalizumab in pediatric multiple sclerosis patients , 2010, Therapeutic advances in neurological disorders.

[27]  L. Krupp,et al.  Pediatric multiple sclerosis , 2009, Annals of Indian Academy of Neurology.

[28]  P. Huppke,et al.  Natalizumab use in pediatric multiple sclerosis. , 2008, Archives of neurology.

[29]  Lauren B. Krupp,et al.  Consensus definitions proposed for pediatric multiple sclerosis and related disorders , 2007, Neurology.

[30]  J. Becho,et al.  The prevalence of multiple sclerosis in the District of Santarém, Portugal , 2006, Journal of Neurology.

[31]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[32]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[33]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[34]  E. Leray,et al.  Epidemiology of multiple sclerosis. , 2016, Revue neurologique.

[35]  L. Ramió-Torrentá,et al.  Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[36]  B. Healy,et al.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. , 2009, Archives of neurology.